Raymond James & Associates’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $32.4K | Sell |
12,458
-1,111
| -8% | -$2.89K | ﹤0.01% | 3851 |
|
|
2024
Q2 | $40.2K | Sell |
13,569
-105
| -0.8% | -$311 | ﹤0.01% | 3773 |
|
|
2024
Q1 | $61.9K | Buy |
13,674
+1,288
| +10% | +$5.84K | ﹤0.01% | 3745 |
|
|
2023
Q4 | $70.7K | Sell |
12,386
-3,746
| -23% | -$21.4K | ﹤0.01% | 3636 |
|
|
2023
Q3 | $74.2K | Sell |
16,132
-36,692
| -69% | -$169K | ﹤0.01% | 3611 |
|
|
2023
Q2 | $341K | Buy |
52,824
+5,691
| +12% | +$36.8K | ﹤0.01% | 3142 |
|
|
2023
Q1 | $355K | Buy |
47,133
+26,744
| +131% | +$202K | ﹤0.01% | 3109 |
|
|
2022
Q4 | $207K | Sell |
20,389
-2,076
| -9% | -$21K | ﹤0.01% | 3409 |
|
|
2022
Q3 | $222K | Buy |
22,465
+4,287
| +24% | +$42.4K | ﹤0.01% | 3358 |
|
|
2022
Q2 | $194K | Buy |
18,178
+2,186
| +14% | +$23.3K | ﹤0.01% | 3489 |
|
|
2022
Q1 | $156K | Sell |
15,992
-56,734
| -78% | -$553K | ﹤0.01% | 3690 |
|
|
2021
Q4 | $1.04M | Sell |
72,726
-53,625
| -42% | -$767K | ﹤0.01% | 2587 |
|
|
2021
Q3 | $2.53M | Buy |
126,351
+7,448
| +6% | +$149K | ﹤0.01% | 1931 |
|
|
2021
Q2 | $2.62M | Buy |
118,903
+46,007
| +63% | +$1.01M | ﹤0.01% | 1905 |
|
|
2021
Q1 | $2.48M | Buy |
+72,896
| New | +$2.48M | ﹤0.01% | 1867 |
|